Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Falces-Romero, Iker  [Clear All Filters]
2024
Lahmer T, Salmanton-García J, Marchesi F, El-Ashwah S, Nucci M, Besson C, Itri F, Jaksic O, Čolović N, Weinbergerova B, et al. Correction: Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey. Infection. 2024.
Salmanton-García J, Marchesi F, Farina F, Weinbergerova B, Itri F, Dávila-Valls J, Martín-Pérez S, Glenthøj A, Hersby DStampe, da Silva MGomes, et al. Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022. EClinicalMedicine. 2024;71:102553.
Aiello TFrancesco, Salmanton-García J, Marchesi F, Weinbergerova B, Glenthoj A, van Praet J, Farina F, Dávila-Valls J, Martín-Pérez S, El-Ashwah S, et al. Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA Registry. Haematologica. 2024.
Lahmer T, Salmanton-García J, Marchesi F, El-Ashwah S, Nucci M, Besson C, Itri F, Jaksic O, Čolović N, Weinbergerova B, et al. Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey. Infection. 2024.
2023
Salmanton-García J, Marchesi F, Koehler P, Weinbergerova B, Colović N, Falces-Romero I, Buquicchio C, Farina F, VAN Praet J, Biernat MM, et al. MOLNUPIRAVIR COMPARED TO NIRMATRELVIR/RITONAVIR FOR COVID-19 IN HIGH-RISK PATIENTS WITH HAEMATOLOGICAL MALIGNANCY IN EUROPE. A MATCHED-PAIRED ANALYSIS FROM THE EPICOVIDEHA REGISTRY. Int J Antimicrob Agents. 2023:106952.
Musto P, Salmanton-García J, Sgherza N, Bergantim R, Farina F, Glenthøj A, Seval GCengiz, Weinbergerova B, Bonuomo V, Bilgin YM, et al. Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: Results from the epicovideha registry. Hematol Oncol. 2023.